VIOLIN Logo
VO Banner
Search: for Help
Vaxvec Home
Introduction
Statistics
News and Updates
Vaxvec Vectors
Vaxvec Vaccines
Vaxvec Antigens
VaxvecAg BLAST
Selected Vectors
B. abortus RB51 vector
RSV vaccine vector
SL3261 vaccine vector
VSV vaccine vector
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Ac-CMV-S1 (infectious bronchitis virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004753
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • S1 gene engineering:
    • Type: Recombinant vector construction
    • Description: The BacMam virus Ac-CMV-S1, which expressed the S1 glycoprotein of IBV-M41 (Zhang et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: BV-Dual-S1 expresses the S1 glycoprotein of IBV-M41 on the baculovirus envelope, and is capable of expressing it in mammalian cells (Zhang et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Zhang et al., 2014: Zhang J, Chen XW, Tong TZ, Ye Y, Liao M, Fan HY. BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens. Vaccine. 2014; 32(6); 664-670. [PubMed: 24342247].
AcHERV-sH1N1-HA
Vaccine Information
  • Vaccine Ontology ID: VO_0004653
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: This gene was inserted to a baculovirus vaccine vector (Choi et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Human endogenous retrovirus (HERV) envelope-coated, nonreplicable, baculovirus-based HA vaccine against swine influenza A/California/04/2009(H1N1) hemagglutin (HA) (AcHERV-sH1N1-HA) (Choi et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Choi et al., 2013: Choi JY, Gwon YD, Kim JK, Cho YD, Heo YK, Cho HS, Choi TJ, Poo HR, Oh YK, Kim YB. Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009. PloS one. 2013; 8(11); e80762. [PubMed: 24260476].
AdC68- rabies virus glycoprotein
Vaccine Information
  • Vaccine Ontology ID: VO_0004630
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • G gene engineering:
    • Type: Recombinant vector construction
    • Description: A plasmid vector, termed pSG5rab.gp, that expresses the rabies virus glycoprotein under the control of an SV40 early promoter (Xiang et al., 1994).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein (Xiang et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Xiang et al., 1994: Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994; 199(1); 132-140. [PubMed: 8116236].
Xiang et al., 2014: Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology. 2014; 450-451; 243-249. [PubMed: 24503087].
ALVAC- CDV-H/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004773
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • CDVgp6 haemagglutinin protein H gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • CDVgp5 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: An attenuated canarypox virus (ALVAC) vaccine strain expressing the CDV hemagglutinin (H) and fusion (F) protein genes (ALVAC-HF) (Welter et al., 2000).
  • Immunization Route: intranasal immunization
References
Welter et al., 2000: Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. Journal of virology. 2000; 74(14); 6358-6367. [PubMed: 10864646].
ALVAC-AHSV
Vaccine Information
  • Vaccine Ontology ID: VO_0004725
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) (Guthrie et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
References
Guthrie et al., 2009: Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J, He L, Nordgren R, Gardner IA, Maclachlan NJ. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine. 2009; 27(33); 4434-4438. [PubMed: 19490959].
ALVAC-AI-H5
Vaccine Information
  • Vaccine Ontology ID: VO_0004747
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: ALVAC vaccine expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) in pig(Kyriakis et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
References
Kyriakis et al., 2009: Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine. 2009; 27(16); 2258-2264. [PubMed: 19428840].
ALVAC-AI-H5(H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004730
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Fowlpox (FP)-vectored avian influenza (FP-AI) (Bublot et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Bublot et al., 2010: Bublot M, Richard-Mazet A, Chanavat-Bizzini S, Le Gros FX, Duboeuf M, Stoll A, Palfi V, Niqueux E, Guionie O, Dren N. Immunogenicity of poxvirus vector avian influenza vaccines in Muscovy and Pekin ducks. Avian diseases. 2010; 54(1 Suppl); 232-238. [PubMed: 20521637].
ALVAC-BTV-CP(VP2/VP5)
Vaccine Information
  • Vaccine Ontology ID: VO_0004732
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: (Boone et al., 2007) recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17
  • Immunization Route: Intramuscular injection (i.m.)
References
Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].
ALVAC-BTV-VP2/VP5
Vaccine Information
  • Vaccine Ontology ID: VO_0004726
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A recombinant canarypox virus vector was used to co-express genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus (Boone et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].
ALVAC-EIV (equine influenza virus H3N8)
Vaccine Information
  • Vaccine Ontology ID: VO_0004735
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • hemagglutinin gene engineering:
    • Type: Recombinant protein preparation
    • Description: A new live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) (Paillot et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) (Paillot et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Paillot et al., 2006: Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Veterinary immunology and immunopathology. 2006; 112(3-4); 225-233. [PubMed: 16621023].
ALVAC-FL- env/gag
Vaccine Information
  • Vaccine Ontology ID: VO_0004740
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env from FeLV-A/Glasgow gene engineering:
    • Type: Recombinant vector construction
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant protein preparation
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes (Tartaglia et al., 1993).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tartaglia et al., 1993: Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. Journal of virology. 1993; 67(4); 2370-2375. [PubMed: 8383248].
ALVAC-HIV-2
Vaccine Information
  • Vaccine Ontology ID: VO_0004727
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env gene engineering:
    • Type: Recombinant vector construction
    • Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant vector construction
    • Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Immunization Route: Intramuscular injection (i.m.)
References
Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].
ALVAC-HIV-2- env/gag/pol
Vaccine Information
  • Vaccine Ontology ID: VO_0004737
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env gene engineering:
    • Type: Recombinant vector construction
    • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant vector construction
    • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Immunization Route: Intramuscular injection (i.m.)
References
Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].
ALVAC-JEV
Vaccine Information
  • Vaccine Ontology ID: VO_0004777
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).
  • Immunization Route: Intramuscular injection (i.m.)
References
Raengsakulrach et al., 1999: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. The American journal of tropical medicine and hygiene. 1999; 60(3); 343-349. [PubMed: 10466959].
ALVAC-MV-HA/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004741
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
    • Detailed Gene Information: Click Here.
  • H hemagglutinin protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
ALVAC-NiV-F
Vaccine Information
  • Vaccine Ontology ID: VO_0004734
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • G glycoprotein gene engineering:
    • Type: Recombinant protein preparation
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Canarypox virus-based vaccine vectors carrying the fusion protein (ALVAC-F) (Weingartl et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Weingartl et al., 2006: Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge. Journal of virology. 2006; 80(16); 7929-7938. [PubMed: 16873250].
ALVAC-NiV-G
Vaccine Information
  • Vaccine Ontology ID: VO_0004733
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • G glycoprotein gene engineering:
    • Type: Recombinant protein preparation
    • Description: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) or the fusion protein (ALVAC-F) (Weingartl et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Canarypox virus-based vaccine vectors carrying the gene for NiV glycoprotein (ALVAC-G) (Weingartl et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Weingartl et al., 2006: Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge. Journal of virology. 2006; 80(16); 7929-7938. [PubMed: 16873250].
ALVAC-RHDV (vCP309)
Vaccine Information
  • Vaccine Ontology ID: VO_0004738
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: An ALVAC (canarypox)-based recombinant virus ALVAC-RHDV (vCP309) expressing a native rabbit hemorrhagic disease virus (RHDV) capsid protein was derived and assessed for its protective efficacy in rabbits (Fischer et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
References
Fischer et al., 1997: Fischer L, Le Gros FX, Mason PW, Paoletti E. A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge. Vaccine. 1997; 15(1); 90-96. [PubMed: 9041672].
ALVAC-RV
Vaccine Information
  • Vaccine Ontology ID: VO_0004728
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A non-adjuvanted feline rabies vaccine developed using the canarypoxvirus vector (Jas et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Jas et al., 2012: Jas D, Coupier C, Toulemonde CE, Guigal PM, Poulet H. Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine. Vaccine. 2012; 30(49); 6991-6996. [PubMed: 23059358].
ALVAC-SIV/gp120
Vaccine Information
  • Vaccine Ontology ID: VO_0004638
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
ALVAC-WNV-prM/E
Vaccine Information
  • Vaccine Ontology ID: VO_0004731
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Three commercially available equine WNV vaccines in horses: (i) an inactivated WNV vaccine (K-WN), (ii) a modified-live vaccine (CP-WN) containing the WNV prM and E proteins expressed by a canarypox vector, (iii) a live-chimera vaccine (WN-FV) containing WNV prM and E proteins expressed in a YF17D vector (Seino et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Seino et al., 2007: Seino KK, Long MT, Gibbs EP, Bowen RA, Beachboard SE, Humphrey PP, Dixon MA, Bourgeois MA. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clinical and vaccine immunology : CVI. 2007; 14(11); 1465-1471. [PubMed: 17687109].
ALVAC-WNV-PrM/E (dogs and cats)
Vaccine Information
  • Vaccine Ontology ID: VO_0004736
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • PrM gene engineering:
    • Type: Recombinant vector construction
    • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
    • Detailed Gene Information: Click Here.
  • E protein gene engineering:
    • Type: Recombinant vector construction
    • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Canarypox vector expressing PrM and E genes of West Nile virus (WNV) (ALVAC-WNV) (Karaca et al., 2005).
  • Immunization Route: Intramuscular injection (i.m.)
References
Karaca et al., 2005: Karaca K, Bowen R, Austgen LE, Teehee M, Siger L, Grosenbaugh D, Loosemore L, Audonnet JC, Nordgren R, Minke JM. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine. 2005; 23(29); 3808-3813. [PubMed: 15893618].
BacMam-sHAPQ
Vaccine Information
  • Vaccine Ontology ID: VO_0004655
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
BoHV-4-A-gD(cp)gD(106)ΔTK
Vaccine Information
  • Vaccine Ontology ID: VO_0004685
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: The bovine herpesvirus 4 (BoHV-4) based vector derived from an apathogenic isolate of BoHV-4 was used to express the immunodominant CpHV-1 glycoprotein D (BoHV-4-A-gD(cp)gD(106)ΔTK) (Donofrio et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Donofrio et al., 2013: Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M, Cavirani S, Marinaro M, Grandolfo E, Buonavoglia C, Tempesta M. Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD. PloS one. 2013; 8(1); e52758. [PubMed: 23300989].
BoHV-4-A-IgK-VP2gD
Vaccine Information
  • Vaccine Ontology ID: VO_0004686
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Cattle
  • Vector:
  • Preparation: BoHV-4-based vector cloned as a bacterial artificial chromosome (BAC) was engineered to express the bluetongue virus (BTV) immune-dominant glycoprotein VP2 provided of a heterologous signal peptide to its amino terminal and a trans-membrane domain to its carboxyl terminal (IgK-VP2gDtm), to allow VP2 expression targeting to the cell membrane fraction (Franceschi et al., 2011).
  • Immunization Route: Other
References
Franceschi et al., 2011: Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine. 2011; 29(16); 3074-3082. [PubMed: 21320537].
BPZE1- FHA (H1N1/PR8 influenza A virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004650
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) gene engineering:
    • Type: Recombinant protein preparation
    • Description: One, two and three copies of the Cys-containing ectodomain of matrix protein 2 (M2e) from influenza A virus were genetically fused to full length FHA and expressed in BPZE1 (Li et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: One, two and three copies of the Cys-containing ectodomain of matrix protein 2 (M2e) from influenza A virus were genetically fused to full length FHA and expressed in BPZE1 (Li et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Li et al., 2011: Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, Alonso S. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine. 2011; 29(33); 5502-5511. [PubMed: 21624415].
BV-GD-ORF2
Vaccine Information
  • Vaccine Ontology ID: VO_0004754
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: B aculovirus was used to develop a novel candidate vaccine for a preventive or therapeutic strategy to control PCV2 infections (Ye et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Ye et al., 2013: Ye Y, Cheng X, Zhang J, Tong T, Lin W, Liao M, Fan H. Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2. Virology journal. 2013; 10; 316. [PubMed: 24161107].
BV-H5/H7/H9
Vaccine Information
  • Vaccine Ontology ID: VO_0004654
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1)) gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant virus-like particle (VLP) that co-localizes hemagglutinin (HA) proteins derived from H5N1, H7N2, and H9N2 viruses (Tretyakova et al., 2013).
    • Detailed Gene Information: Click Here.
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant virus-like particle (VLP) that co-localizes hemagglutinin (HA) proteins derived from H5N1, H7N2, and H9N2 viruses (Tretyakova et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A baculovirus vector co-expressing the H5, H7, and H9 genes from A/Viet Nam/1203/2004 (H5N1), A/New York/107/2003 (H7N2) and A/Hong Kong/33982/2009 (H9N2) viruses, respectively, as well as neuraminidase (NA) and matrix (M1) genes from A/Puerto Rico/8/1934 (H1N1) virus (Tretyakova et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tretyakova et al., 2013: Tretyakova I, Pearce MB, Florese R, Tumpey TM, Pushko P. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013; 442(1); 67-73. [PubMed: 23618102].
BV-RVG/RVG
Vaccine Information
  • Vaccine Ontology ID: VO_0004651
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant protein preparation
    • Description: The recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Wu et al., 2014: Wu Q, Yu F, Xu J, Li Y, Chen H, Xiao S, Fu ZF, Fang L. Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model. Veterinary microbiology. 2014; 171(1-2); 93-9101. [PubMed: 24793501].
CAdVa-Filoviruses (EbMarburg viruses)
Vaccine Information
  • Vaccine Ontology ID: VO_0004645
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Musoke Marburgvirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species)
Vaccine Information
  • Vaccine Ontology ID: VO_0004647
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Human
  • GP from Sudan ebolavirus gene engineering:
    • Type: Recombinant protein preparation
    • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant protein preparation
    • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The bivalent cAdVaxE(GPs/z) vaccine includes the SEBOV glycoprotein (GP) and ZEBOV GP genes together in a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Wang et al., 2006: Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Journal of virology. 2006; 80(6); 2738-2746. [PubMed: 16501083].
CAdVax-Den12/Den34
Vaccine Information
  • Vaccine Ontology ID: VO_0004643
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: using a complex adenovirus vector, by incorporating the genes expressing premembrane (prM) and envelope (E) proteins of dengue virus types 1 and 2 (dengue-1 and -2, respectively) (CAdVax-Den12) or dengue-3 and -4 (CAdVax-Den34) (Raviprakash et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
References
Raviprakash et al., 2008: Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. Journal of virology. 2008; 82(14); 6927-6934. [PubMed: 18480438].
CAdVax-Filoviruses (Ebola )
Vaccine Information
  • Vaccine Ontology ID: VO_0004644
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A panfilovirus vaccine based on a complex adenovirus (CAdVax) technology that expresses multiple antigens from five different filoviruses de novo (Swenson et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
References
Swenson et al., 2008: Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH, Dong JY, Pratt WD. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and vaccine immunology : CVI. 2008; 15(3); 460-467. [PubMed: 18216185].
CAdVax-RVFV glycoprotein
Vaccine Information
  • Vaccine Ontology ID: VO_0004642
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: RVFV glycoprotein genes were incorporated into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a RVFV vaccine (Holman et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
References
Holman et al., 2009: Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, Maher EM, Holbrook MR, Dong JY. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clinical and vaccine immunology : CVI. 2009; 16(11); 1624-1632. [PubMed: 19776190].
CAdVax-ZEBOV/SEBOV
Vaccine Information
  • Vaccine Ontology ID: VO_0004641
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A multivalent vaccine candidate (EBO7) that expresses the glycoproteins of Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SEBOV) in a single complex adenovirus-based vector (CAdVax) (Pratt et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Pratt et al., 2010: Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical and vaccine immunology : CVI. 2010; 17(4); 572-581. [PubMed: 20181765].
cAdVaxM(fus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004646
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Musoke Marburgvirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
CVB4/p24(73(3))
Vaccine Information
  • Vaccine Ontology ID: VO_0004719
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A live coxsackievirus B4 recombinant, CVB4/p24(73(3)), that expresses seventy-three amino acids of the gag p24 sequence (HXB2) (Gu et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Gu et al., 2010: Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses. PloS one. 2010; 5(9); . [PubMed: 20824074].
dVV-HA5(H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004787
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1)) gene engineering:
    • Type: Recombinant vector construction
    • Description: H5N1 live vaccine, dVV-HA5, expressing the hemagglutinin of a virulent clade 1 H5N1 strain (Mayrhofer et al., 2009).
    • Detailed Gene Information: Click Here.
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: H5N1 live vaccine, dVV-HA5, expressing the hemagglutinin of a virulent clade 1 H5N1 strain (Mayrhofer et al., 2009).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Replication-deficient vaccinia virus vector H5N1 live vaccine, dVV-HA5, expressing the hemagglutinin of a virulent clade 1 H5N1 strain (Mayrhofer et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
References
Mayrhofer et al., 2009: Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of virology. 2009; 83(10); 5192-5203. [PubMed: 19279103].
Ebola virus recombinant adenovirus vaccine AdC7-ZGP encoding GP
Vaccine Information
  • Vaccine Ontology ID: VO_0004382
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Vector adenoviral (ADV) expressed the Ebola envelope glycoprotein (GP) (Kobinger et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
Kobinger et al., 2006: Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006; 346(2); 394-401. [PubMed: 16356525].
Ebola virus recombinant adenovirus vector vaccine ADV−GP/NP
Vaccine Information
  • Vaccine Ontology ID: VO_0004072
  • Type: Recombinant vector vaccine
  • Status: Research
  • GP from Zaire ebolavirus gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector adenoviral (ADV) expressed Ebola glycoprotein (GP) (Sullivan et al., 2003b).
    • Detailed Gene Information: Click Here.
  • NP from Zaire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Description: Vector adenoviral (ADV) expressed Ebola nucleoprotein (NP) (Sullivan et al., 2003b).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: To make ADV-GP, the BamHI/EcoRI fragment of GP(Z) was digested from PGEM-3Zf(-)-GP, treated with Klenow, and inserted into HindIII/XbaI/Kle/CIP-treated pRc/CMV plasmid. The resulting plasmid was digested by NruI/DraIII and treated with Klenow. The NruI/DraIII/Kle fragment containing the CMV enhancer, GP(Z) DNA and bovine growth hormone polyadenylation signal was inserted into the BgIII site of the adenoviral shuttle plasmid pAdBgIII26. The adenovirus, a first generation dl 309-based Ad5 vector, contained a deletion in E1 to render the vector replication defective and a partial deletion/substitution in E3, which disrupts the coding sequences for the E3 proteins with a relative molecular mass of 14,700, 14,500 and 10,400, respectively (Sullivan et al., 2000).
  • Virulence:
  • Description: ADV−GP consists of an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) (Sullivan et al., 2003).
References
Sullivan et al., 2000: Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30; 408(6812); 605-9. [PubMed: 11117750].
Sullivan et al., 2003b: Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 7; 424(6949); 681-4. [PubMed: 12904795].
Ebola virus recombinant VSVΔG-GP encoding GP
Vaccine Information
  • Vaccine Ontology ID: VO_0004336
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Macaque
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Vector VSVΔG expressed GP from ZEBOV (Jones et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector:
    • Vactor Name:
    • VO ID: VO_0001025
    • Description: This vaccine uses a replication competent vesicular stomatitis virus vector (VSV?G) (Jones et al., 2005)
  • Immunization Route: Intramuscular injection (i.m.)
References
Jones et al., 2005: Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature medicine. 2005; 11(7); 786-790. [PubMed: 15937495].
FP-AI-H5(H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004729
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 and the other (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003. (Bublot et al., 2010).
    • Detailed Gene Information: Click Here.
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 and the other (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003. (Bublot et al., 2010).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 and the other (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003 (Bublot et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Bublot et al., 2010: Bublot M, Manvell RJ, Shell W, Brown IH. High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens. Avian diseases. 2010; 54(1 Suppl); 257-261. [PubMed: 20521642].
fp-IBD1
Vaccine Information
  • Vaccine Ontology ID: VO_0004622
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
FP-IBDV-VP2
Vaccine Information
  • Vaccine Ontology ID: VO_0004742
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: A fowlpox virus vector was used to carry the VP2 gene of infectious bursal disease virus (IBDV) fused with β-galactosidase (Butter et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Butter et al., 2013) fp-IBD1, which consists of a fowlpox virus vector carrying the VP2 gene of infectious bursal disease virus (IBDV) fused with β-galactosidase.
  • Immunization Route: Intramuscular injection (i.m.)
References
Butter et al., 2013: Butter C, Staines K, van Hateren A, Davison TF, Kaufman J. The peptide motif of the single dominantly expressed class I molecule of the chicken MHC can explain the response to a molecular defined vaccine of infectious bursal disease virus (IBDV). Immunogenetics. 2013; 65(8); 609-618. [PubMed: 23644721].
FPV-LT vaccine
Vaccine Information
  • Vaccine Ontology ID: VO_0004624
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: Viral vector vaccines using fowl poxvirus (FPV) and herpesvirus of turkey (HVT) as vectors and carrying infectious laryngotracheitis virus (ILTV) genes (Vagnozzi et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
HDAd-sFsyn
Vaccine Information
  • Vaccine Ontology ID: VO_0004802
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: (Fu et al., 2014)
  • Immunization Route: Intramuscular injection (i.m.)
References
Fu et al., 2014: Fu YH, Jiao YY, He JS, Giang GY, Zhang W, Yan YF, Ma Y, Hua Y, Zhang Y, Peng XL, Shi CX, Hong T. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. Antiviral research. 2014; 105; 72-79. [PubMed: 24560779].
HSVT[VP7/6/2]
Vaccine Information
  • Vaccine Ontology ID: VO_0004687
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: HSV-1 amplicon vectors encoding individual or multiple structural RV proteins from a polycistronic transgene cassette in mammalian cells (Laimbacher et al., 2012).
    • Detailed Gene Information: Click Here.
  • VP6 gene engineering:
    • Type: Recombinant vector construction
    • Description: HSV-1 amplicon vectors encoding individual or multiple structural RV proteins from a polycistronic transgene cassette in mammalian cells (Laimbacher et al., 2012).
    • Detailed Gene Information: Click Here.
  • VP7 gene engineering:
    • Type: Recombinant vector construction
    • Description: HSV-1 amplicon vectors encoding individual or multiple structural RV proteins from a polycistronic transgene cassette in mammalian cells (Laimbacher et al., 2012).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Herpes simplex virus type 1 (HSV-1) amplicon vectors were constructed to coexpress the rotavirus (RV) structural genes VP2, VP6, and VP7 (Laimbacher et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Laimbacher et al., 2012: Laimbacher AS, Esteban LE, Castello AA, Abdusetir Cerfoglio JC, Argüelles MH, Glikmann G, D'Antuono A, Mattion N, Berois M, Arbiza J, Hilbe M, Schraner EM, Seyffert M, Dresch C, Epstein AL, Ackermann M, Fraefel C. HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice. Molecular therapy : the journal of the American Society of Gene Therapy. 2012; 20(9); 1810-1820. [PubMed: 22713696].
HVT-ILT(FC-126 strain)
Vaccine Information
  • Vaccine Ontology ID: VO_0004756
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Turkey herpesvirus vector laryngotracheitis vaccine (HVT/LT) expressing the glycoprotein B gene of laryngotracheitis virus (LTV) (Esaki et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Esaki et al., 2013: Esaki M, Noland L, Eddins T, Godoy A, Saeki S, Saitoh S, Yasuda A, Dorsey KM. Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens. Avian diseases. 2013; 57(2); 192-198. [PubMed: 24689173].
HVT-LT
Vaccine Information
  • Vaccine Ontology ID: VO_0004793
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Viral vector vaccines using fowl poxvirus (FPV) and herpesvirus of turkey (HVT) as vectors and carrying infectious laryngotracheitis virus (ILTV) genes (Vagnozzi et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Vagnozzi et al., 2012: Vagnozzi A, Zavala G, Riblet SM, Mundt A, García M. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens. Avian pathology : journal of the W.V.P.A. 2012; 41(1); 21-31. [PubMed: 22845318].
HVT-ND
Vaccine Information
  • Vaccine Ontology ID: VO_0004632
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant vector construction
    • Description: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A turkey herpesvirus vector Newcastle disease vaccine (HVT/ND) expressing the fusion gene of Newcastle disease virus (NDV) (Esaki et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Esaki et al., 2013: Esaki M, Godoy A, Rosenberger JK, Rosenberger SC, Gardin Y, Yasuda A, Dorsey KM. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine. Avian diseases. 2013; 57(4); 750-755. [PubMed: 24597117].
L. T -HIV-1 Gag
Vaccine Information
  • Vaccine Ontology ID: VO_0004629
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Gag from HIV 1 gene engineering:
    • Type: Recombinant vector construction
    • Description: A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Breton et al., 2007: Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. The Journal of general virology. 2007; 88(Pt 1); 217-225. [PubMed: 17170454].
LM1-2-E7
Vaccine Information
  • Vaccine Ontology ID: VO_0004803
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • E7 Type 16 gene engineering:
    • Type: Recombinant vector construction
    • Description: The E7 gene is inserted into the vector of Listeria monocytogenes, strain LM1-2 (Jia et al., 2012).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The E7 fragment was amplified with PCR then cloned into the chromosome of L. monocytogenes (Jia et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Jia et al., 2012: Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model. International journal of molecular medicine. 2012; 30(6); 1335-1342. [PubMed: 23027427].
MVA-CHIKV
Vaccine Information
  • Vaccine Ontology ID: VO_0004666
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: The highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) was used to express the CHIKV C, E3, E2, 6K, and E1 structural genes (termed MVA-CHIKV) (García-Arriaza et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
García-Arriaza et al., 2014: García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. Journal of virology. 2014; 88(6); 3527-3547. [PubMed: 24403588].
MVTT-HA-QH
Vaccine Information
  • Vaccine Ontology ID: VO_0004667
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: MVTTHA-QH and MVTTHA-AH, which expresses the H5 gene of a goose-derived Qinghai strain A/Bar-headed Goose/Qinghai/1/2005 or human-derived Anhui Strain A/Anhui/1/2005 (Xiao et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Xiao et al., 2013: Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, Li Z, Yuen KY, Ho DD, Gao GF, Chen Z. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PloS one. 2013; 8(12); e83274. [PubMed: 24358269].
Myxoma-FCV
Vaccine Information
  • Vaccine Ontology ID: VO_0004707
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
NYVAC- CDV-H/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004772
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • CDVgp6 haemagglutinin protein H gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • CDVgp5 gene engineering:
    • Type: Recombinant vector construction
    • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: An attenuated vaccinia virus (NYVAC) vaccine strain expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF) (Welter et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
References
Welter et al., 2000: Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. Journal of virology. 2000; 74(14); 6358-6367. [PubMed: 10864646].
NYVAC-EHV-1- vP1014
Vaccine Information
  • Vaccine Ontology ID: VO_0004771
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: vP1014, a vaccinia-based construct (NYVAC) coding for the immediate early gene (gene 64) of EHV-1 (Paillot et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
NYVAC-HIV-1
Vaccine Information
  • Vaccine Ontology ID: VO_0004774
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
References
Patterson et al., 2000: Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques. AIDS (London, England). 2000; 14(16); 2445-2455. [PubMed: 11101054].
NYVAC-HIV-2
Vaccine Information
  • Vaccine Ontology ID: VO_0004775
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
References
Patterson et al., 2000: Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques. AIDS (London, England). 2000; 14(16); 2445-2455. [PubMed: 11101054].
NYVAC-JEV
Vaccine Information
  • Vaccine Ontology ID: VO_0004776
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).
  • Immunization Route: Intramuscular injection (i.m.)
References
Raengsakulrach et al., 1999: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. The American journal of tropical medicine and hygiene. 1999; 60(3); 343-349. [PubMed: 10466959].
NYVAC-JEV- prM/E/ NS1
Vaccine Information
  • Vaccine Ontology ID: VO_0004780
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • PrM gene engineering:
    • Type: Recombinant vector construction
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • NS1 gene engineering:
    • Type: Recombinant vector construction
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • E gene engineering:
    • Type: Recombinant protein preparation
    • Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
  • Immunization Route: Intramuscular injection (i.m.)
References
Konishi et al., 1992: Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 1992; 190(1); 454-458. [PubMed: 1326813].
NYVAC-PRV- gII/ gp50
Vaccine Information
  • Vaccine Ontology ID: VO_0004778
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GII gene engineering:
    • Type: Recombinant vector construction
    • Description: A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996).
    • Detailed Gene Information: Click Here.
  • gp50 gene engineering:
    • Type: Recombinant vector construction
    • Description: A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Brockmeier and Mengeling, 1996) A NYVAC vaccinia vector containing genes for PRV gII and gp50 .
  • Immunization Route: Intramuscular injection (i.m.)
References
Brockmeier and Mengeling, 1996: Brockmeier SL, Mengeling WL. Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1996; 60(4); 315-317. [PubMed: 8904669].
NYVAC-SIV
Vaccine Information
  • Vaccine Ontology ID: VO_0004779
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998).
  • Immunization Route: Intramuscular injection (i.m.)
References
Benson et al., 1998: Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. Journal of virology. 1998; 72(5); 4170-4182. [PubMed: 9557706].
PAV3-HA (A/Hanoi/30408/2005 H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004696
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
PAV3-HA (H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004695
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Replication-incompetent porcine adenovirus 3 (PAV3) vector (Patel et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Patel et al., 2010: Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PloS one. 2010; 5(12); e15301. [PubMed: 21179494].
pRP-RSV-HSV-1-gB
Vaccine Information
  • Vaccine Ontology ID: VO_0004723
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • gB gene engineering:
    • Type: Recombinant vector construction
    • Description: The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV (Manservigi et al., 1990).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
PrV-HA (swine-origin H1N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004698
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Pseudorabies virus (PrV) strain Bartha (PrV-Ba) served as a vector for the expression of haemagglutinin (HA) of swine-origin H1N1 virus (Klingbeil et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The pseudorabies virus (PrV) strain Bartha (PrV-Ba) was used as vector for the expression of haemagglutinin (HA) of swine-origin H1N1 virus (Klingbeil et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Klingbeil et al., 2014: Klingbeil K, Lange E, Teifke JP, Mettenleiter TC, Fuchs W. Immunization of pigs with an attenuated pseudorabies virus recombinant expressing the haemagglutinin of pandemic swine origin H1N1 influenza A virus. The Journal of general virology. 2014; 95(Pt 4); 948-959. [PubMed: 24431235].
PrV-PCV2-ORF2
Vaccine Information
  • Vaccine Ontology ID: VO_0004699
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • ORF2 gene engineering:
    • Type: Recombinant vector construction
    • Description: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO; the genome of PRV attenuated vaccine and the transfer plasmid pGO were transfected by using Lipofectamine 2000 Reagent into swine testis cells for homologous recombination to obtain the recombinant PRV (Chao et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO (Chao et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Chao et al., 2014: Chao A, Fu P, Guo X, Gao X, Cui B, Chen H. [Immune efficacy in mice by recombinant pseudorabies virus PGO expressing ORF2 gene of porcine circovirus type 2]. Wei sheng wu xue bao = Acta microbiologica Sinica. 2014; 54(2); 211-217. [PubMed: 24818470].
PUREVAXFerret Distemper
Vaccine Information
  • Tradename: PUREVAXFerret Distemper
  • Manufacturer: Merial
  • Vaccine Ontology ID: VO_0001159
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Canarypox virus-vectored vaccine
References
 
rAd-GP (Ebola virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004631
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (O'Brien et al., 2014)
  • Immunization Route: Intramuscular injection (i.m.)
References
O'Brien et al., 2014: O'Brien LM, Stokes MG, Lonsdale SG, Maslowski DR, Smither SJ, Lever MS, Laws TR, Perkins SD. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse. Virology. 2014; 452-453; 324-333. [PubMed: 24461913].
rAdV-SFV-E2
Vaccine Information
  • Vaccine Ontology ID: VO_0004700
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Pig
  • Vector:
  • Preparation: An adenovirus-vectored Semliki forest virus replicon construct expressing the E2 glycoprotein from CSFV, rAdV-SFV-E2 (Sun et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Sun et al., 2013: Sun Y, Tian DY, Li S, Meng QL, Zhao BB, Li Y, Li D, Ling LJ, Liao YJ, Qiu HJ. Comprehensive evaluation of the adenovirus/alphavirus-replicon chimeric vector-based vaccine rAdV-SFV-E2 against classical swine fever. Vaccine. 2013; 31(3); 538-544. [PubMed: 23153441].
rAPMV3-F (newcastle disease)
Vaccine Information
  • Vaccine Ontology ID: VO_0004684
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • F fusion protein gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant viruses, rAPMV3-F and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins (Kumar et al., 2011).
    • Detailed Gene Information: Click Here.
  • HN hemagglutinin-neuraminidase gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant viruses, rAPMV3-F and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins (Kumar et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant virus, rAPMV3-F generated expressinv the NDV fusion protein (Kumar et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Kumar et al., 2011: Kumar S, Nayak B, Collins PL, Samal SK. Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens. Journal of virology. 2011; 85(13); 6521-6534. [PubMed: 21525340].
rBCG-SIVgag
Vaccine Information
  • Vaccine Ontology ID: VO_0004789
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Macaque
  • Antigen: M. bovis BCG-SIV Gag followed by boosting with rDIsSIVgag (Ami et al., 2005).
  • gag gene engineering:
    • Type: Recombinant vector construction
    • Description: The SIV gag gene was used in generation of a recombinant vector vaccine (Ami et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Immunization Route: Intradermal injection (i.d.)
References
Ami et al., 2005: Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. Journal of virology. 2005; 79(20); 12871-12879. [PubMed: 16188989].
rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine
Vaccine Information
  • Vaccine Ontology ID: VO_0004600
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: cynomologus macaque
  • Antigen: gag from simian immunodeficiency viruses
  • gag gene engineering:
    • Type: Recombinant vector construction
    • Description: The SHIV gag gene was inserted to a recombinant BCG vector and a replication-deficient vaccinia virus strain (DIs) vaccine vector (Ami et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector:
    • Vactor Name:
    • VO ID: VO_0001023
    • Description: Mycobacterium bovis bacillus Calmette-Guérin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) (Ami et al., 2005)
  • Immunization Route: Intramuscular injection (i.m.)
References
Ami et al., 2005: Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. Journal of virology. 2005; 79(20); 12871-12879. [PubMed: 16188989].
RBD-rAAV-SARS-CoV
Vaccine Information
  • Vaccine Ontology ID: VO_0004678
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Vector:
  • Preparation: Inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant (Zheng et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
References
Zheng et al., 2008: Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Studies of SARS virus vaccines. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2008; 14 Suppl 4; 39-43. [PubMed: 18708674].
RBD-rAAV-SARS-CoV-version-02
Vaccine Information
  • Vaccine Ontology ID: VO_0004679
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Vector:
  • Preparation: RBD-rAAV prime/RBD-specific T cell peptide boost (Du et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
References
Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].
rCMV- EBOV
Vaccine Information
  • Vaccine Ontology ID: VO_0004717
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • NP from Zaire Ebola virus gene engineering:
    • Type: Recombinant protein preparation
    • Description: A mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NP(CTL)) (Tsuda et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NP(CTL)) (Tsuda et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tsuda et al., 2011: Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS neglected tropical diseases. 2011; 5(8); e1275. [PubMed: 21858240].
RCN-HA (H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004691
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: Recombinant raccoonpox (RCN) virus acted as a vector to express the hemagglutinin (HA) from H5N1 viruses (Kingstad-Bakke et al., 2012).
  • Immunization Route: Intradermal injection (i.d.)
References
Kingstad-Bakke et al., 2012: Kingstad-Bakke B, Brewoo JN, Mai le Q, Kawaoka Y, Osorio JE. Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice. Vaccine. 2012; 30(45); 6402-6408. [PubMed: 22921740].
RCN-rabies-G
Vaccine Information
  • Vaccine Ontology ID: VO_0004693
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 1999).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 2003).
  • Immunization Route: Intramuscular injection (i.m.)
References
Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].
Osorio et al., 2003: Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT. Raccoon poxvirus as a mucosal vaccine vector for domestic cats. Journal of drug targeting. 2003; 11(8-10); 463-470. [PubMed: 15203914].
rCPV-BTV-Cpox
Vaccine Information
  • Vaccine Ontology ID: VO_0004788
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: BTV recombinant capripoxviruses (BTV-Cpox) individually expressing four different genes encoding two capsid proteins (VP2 and VP7) and two non-structural proteins (NS1, NS3) of BTV serotype 2 (BTV-2) (Perrin et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Perrin et al., 2007: Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine. 2007; 25(37-38); 6774-6783. [PubMed: 17669563].
rDEV-re6 (H5)
Vaccine Information
  • Vaccine Ontology ID: VO_0004623
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: A recombinant duck enteritis virus was generated that expresses the HA gene of an H5N1 virus (rDEV-re6) (Liu et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Liu et al., 2013: Liu J, Chen P, Jiang Y, Deng G, Shi J, Wu L, Lin Y, Bu Z, Chen H. Recombinant duck enteritis virus works as a single-dose vaccine in broilers providing rapid protection against H5N1 influenza infection. Antiviral research. 2013; 97(3); 329-333. [PubMed: 23267833].
rDEV-us78HA
Vaccine Information
  • Vaccine Ontology ID: VO_0004658
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: rDEV-ul41HA and rDEV-us78HA, in which the hemagglutinin (HA) gene of the H5N1 virus A/duck/Anhui/1/06 was inserted and stably maintained within the ul41 gene or between the us7 and us8 genes of the DEV genome (Liu et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Liu et al., 2011: Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. Journal of virology. 2011; 85(21); 10989-10998. [PubMed: 21865383].
rFP-RPV-H/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004752
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Rinderpest virus (RPV) antigens, expressed in pox virus vectors (Jones et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
References
Jones et al., 1997: Jones L, Tenorio E, Gorham J, Yilma T. Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus. American journal of veterinary research. 1997; 58(6); 590-593. [PubMed: 9185963].
rFPV-AI-H5A-IL6
Vaccine Information
  • Vaccine Ontology ID: VO_0004743
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant fowlpox virus (rFPV-AIH5AIL6) coexpressing the haemagglutinin (HA) gene of the H5N1 subtype of the avian influenza virus (AIV) and chicken interleukin 6 gene (Qian et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Qian et al., 2012: Qian C, Chen S, Ding P, Chai M, Xu C, Gan J, Peng D, Liu X. The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks. Vaccine. 2012; 30(44); 6279-6286. [PubMed: 22902682].
rFPV-H5AI-L2
Vaccine Information
  • Vaccine Ontology ID: VO_0004746
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant fowlpox virus coexpressing the inserted HA and chiIL2 genes (rFPV-H5AIL2). (Yun et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
References
Yun et al., 2009: Yun SL, Zhang W, Liu WJ, Zhang XR, Chen SJ, Wu YT, Peng DX, Liu XF. [Construction of recombinant fowlpox virus coexpressing HA gene from H5N1 avian influenza virus and chicken interleukin-2 gene and assessment of its protective efficacy]. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui]. 2009; 25(6); 430-436. [PubMed: 20077933].
rFPV-IBDV-VP 2.4.3
Vaccine Information
  • Vaccine Ontology ID: VO_0004750
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2-VP4-VP3 gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant FPV-VP 2.4.3 contained the gene for the VP 2-VP4-VP3 polyprotein under the control of the vaccinia virus late promoter P.L 11 inserted within the thymidine kinase (TK) gene of FPV (Heine and Boyle, 1993).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant FPV-VP 2.4.3 contained the gene for the VP 2-VP4-VP3 polyprotein under the control of the vaccinia virus late promoter P.L 11 inserted within the thymidine kinase (TK) gene of FPV (Heine and Boyle, 1993).
  • Immunization Route: Intramuscular injection (i.m.)
References
Heine and Boyle, 1993: Heine HG, Boyle DB. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Archives of virology. 1993; 131(3-4); 277-292. [PubMed: 8394069].
rFPV-IBDV-VP2
Vaccine Information
  • Vaccine Ontology ID: VO_0004625
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tsukamoto et al., 2000: Tsukamoto K, Sato T, Saito S, Tanimura N, Hamazaki N, Mase M, Yamaguchi S. Dual-viral vector approach induced strong and long-lasting protective immunity against very virulent infectious bursal disease virus. Virology. 2000; 269(2); 257-267. [PubMed: 10753704].
rFPV-ILTV
Vaccine Information
  • Vaccine Ontology ID: VO_0004744
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: ILTV viral vector recombinant vaccines (Johnson et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Johnson et al., 2010: Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, García M. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines. Avian diseases. 2010; 54(4); 1251-1259. [PubMed: 21313847].
rFPV-NDV-H/F
Vaccine Information
  • Vaccine Ontology ID: VO_0004751
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: (Boursnell et al., 1990)
  • Immunization Route: Intramuscular injection (i.m.)
References
Boursnell et al., 1990: Boursnell ME, Green PF, Samson AC, Campbell JI, Deuter A, Peters RW, Millar NS, Emmerson PT, Binns MM. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology. 1990; 178(1); 297-300. [PubMed: 2167557].
rHVT-H5
Vaccine Information
  • Vaccine Ontology ID: VO_0004633
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: A recombinant turkey herpesvirus (rHVT)-AI vaccine, rHVT-H5, was used to express the HA gene of a highly pathogenic avian influenza (HPAI) H5N1 clade 2.2 A/Swan/Hungary/499/ 2006 strain inserted into FC-126 strain of HVT vector (Soejoedono et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Soejoedono et al., 2012: Soejoedono RD, Murtini S, Palya V, Felföldi B, Mató T, Gardin Y. Efficacy of a recombinant HVT-H5 vaccine against challenge with two genetically divergent Indonesian HPAI H5N1 strains. Avian diseases. 2012; 56(4 Suppl); 923-927. [PubMed: 23402113].
rHVT-H5 (clade 2.2 H5N1 HPAIV)
Vaccine Information
  • Vaccine Ontology ID: VO_0004634
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
rLSDV-Rabies-gP
Vaccine Information
  • Vaccine Ontology ID: VO_0004762
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) (Aspden et al., 2003).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Using the rabies virus glycoprotein (RG) as a model antigen, the recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG (Aspden et al., 2003).
  • Immunization Route: Intramuscular injection (i.m.)
References
Aspden et al., 2003: Aspden K, Passmore JA, Tiedt F, Williamson AL. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. The Journal of general virology. 2003; 84(Pt 8); 1985-1996. [PubMed: 12867628].
rLSDV-RPV
Vaccine Information
  • Vaccine Ontology ID: VO_0004763
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant capripox-rinderpest vaccine (Ngichabe et al., 2002).
  • Immunization Route: Intramuscular injection (i.m.)
References
Ngichabe et al., 2002: Ngichabe CK, Wamwayi HM, Ndungu EK, Mirangi PK, Bostock CJ, Black DN, Barrett T. Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiology and infection. 2002; 128(2); 343-349. [PubMed: 12002554].
rMDV-IBDV-VP2
Vaccine Information
  • Vaccine Ontology ID: VO_0004749
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: IBDV host-protective antigen VP2 was expressed in a recombinant vaccine vector (Tsukamoto et al., 2000).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tsukamoto et al., 2000: Tsukamoto K, Sato T, Saito S, Tanimura N, Hamazaki N, Mase M, Yamaguchi S. Dual-viral vector approach induced strong and long-lasting protective immunity against very virulent infectious bursal disease virus. Virology. 2000; 269(2); 257-267. [PubMed: 10753704].
rMV- WNV
Vaccine Information
  • Vaccine Ontology ID: VO_0004712
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A recombinant MV vaccine expressing the secreted form of WNV envelope glycoprotein (Brandler and Tangy, 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Brandler and Tangy, 2013: Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses. 2013; 5(10); 2384-2409. [PubMed: 24084235].
rMV-Ed-G
Vaccine Information
  • Vaccine Ontology ID: VO_0004714
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • G glycoprotein gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Yoneda et al., 2013: Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PloS one. 2013; 8(3); e58414. [PubMed: 23516477].
rMV-SARS-CoV-S/Ssol
Vaccine Information
  • Vaccine Ontology ID: VO_0004711
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Description: A live attenuated recombinant meas(Escriou et al., 2014)s vaccine (MV) candidates expressing either the membrane-anchore SARS-CoV spike (S) protein (Escriou et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol) (Escriou et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Escriou et al., 2014: Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, Février M, Tangy F. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014; 452-453; 32-41. [PubMed: 24606680].
rMVA- AHS-VP2
Vaccine Information
References
Castillo-Olivares et al., 2011: Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PloS one. 2011; 6(1); e16503. [PubMed: 21298069].
rMVA-CCHF
Vaccine Information
  • Vaccine Ontology ID: VO_0004665
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Modified Vaccinia virus Ankara was used to develop a recombinant candidate vaccine expressing the CCHF virus glycoproteins (Buttigieg et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Buttigieg et al., 2014: Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PloS one. 2014; 9(3); e91516. [PubMed: 24621656].
rMVA-GnGc (Rift Valley fever virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004663
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Host Species as Laboratory Animal Model: lambs
  • Vector:
  • Preparation: A modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs (Busquets et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Busquets et al., 2014: Busquets N, Lorenzo G, López-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, Xavier Abad F, Rodríguez F, Bensaid A, Warimwe G, Gilbert SC, Domingo M, Brun A. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral research. 2014; ; . [PubMed: 24933081].
rMVA-SIV-CD40L
Vaccine Information
  • Vaccine Ontology ID: VO_0004664
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
rMVA-SIV-CD40L
Vaccine Information
  • Vaccine Ontology ID: VO_0004792
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Kwa et al., 2014: Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. CD40L-adjuvanted DNA/MVA SIV239 vaccine enhances SIV-specific humoral and cellular immunity, and improves protection against a heterologous SIVE660 mucosal challenge. Journal of virology. 2014; ; . [PubMed: 24920805].
rMVTT-HA-QH (H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004759
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Using a replicating modified vaccinia virus Tian Tan strain (MVTT) as a vaccine vector, MVTTHA-QH and MVTTHA-AH were constructed, which expresses the H5 gene of a goose-derived Qinghai strain A/Bar-headed Goose/Qinghai/1/2005 or human-derived Anhui Strain A/Anhui/1/2005 (Xiao et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Xiao et al., 2013: Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, Li Z, Yuen KY, Ho DD, Gao GF, Chen Z. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PloS one. 2013; 8(12); e83274. [PubMed: 24358269].
rMVTT-SIV-gpe
Vaccine Information
  • Vaccine Ontology ID: VO_0004760
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env from SIV gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
    • Detailed Gene Information: Click Here.
  • Pol SIV gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
    • Detailed Gene Information: Click Here.
  • Pol SIV gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Sun et al., 2013) a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe))
  • Immunization Route: Intramuscular injection (i.m.)
References
Sun et al., 2013: Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Zhu W, Chen L, Zhang L. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. Journal of virology. 2013; 87(10); 5669-5677. [PubMed: 23487457].
rNDV-H5
Vaccine Information
  • Vaccine Ontology ID: VO_0004681
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: Enterotropic NDV vector expressing an H5 haemagglutinin (rNDV-H5) (Ferreira et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
References
Ferreira et al., 2014: Ferreira HL, Rauw F, Pirlot JF, Reynard F, van den Berg T, Bublot M, Lambrecht B. Comparison of single 1-day-old chick vaccination using a Newcastle disease virus vector with a prime/boost vaccination scheme against a highly pathogenic avian influenza H5N1 challenge. Avian pathology : journal of the W.V.P.A. 2014; 43(1); 68-77. [PubMed: 24320551].
rNDV-H5 ( HPAI H5N1 challenge in mule ducks)
Vaccine Information
  • Vaccine Ontology ID: VO_0004682
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Newcastle disease virus (NDV) vector expressing an H5N1 hemagglutinin (rNDV-H5) (Ferreira et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Ferreira et al., 2012: Ferreira HL, Pirlot JF, Reynard F, van den Berg T, Bublot M, Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian diseases. 2012; 56(4 Suppl); 940-948. [PubMed: 23402116].
rNDV-H6
Vaccine Information
  • Vaccine Ontology ID: VO_0004683
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • Vector:
  • Preparation: A recombinant Newcastle disease virus (NDV) expressing H6 hemagglutinin (HA) of a low pathogenic avian influenza virus (LPAIV) was generated by reverse genetics (NDVH6) (Schröer et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Schröer et al., 2011: Schröer D, Veits J, Keil G, Römer-Oberdörfer A, Weber S, Mettenleiter TC. Efficacy of Newcastle disease virus recombinant expressing avian influenza virus H6 hemagglutinin against Newcastle disease and low pathogenic avian influenza in chickens and turkeys. Avian diseases. 2011; 55(2); 201-211. [PubMed: 21793434].
rNDV-ILTV-gD
Vaccine Information
  • Vaccine Ontology ID: VO_0004680
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
rOka-gD2- HSV-2
Vaccine Information
  • Vaccine Ontology ID: VO_0004710
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • gD gene engineering:
    • Type: Recombinant vector construction
    • Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
  • Immunization Route: Intramuscular injection (i.m.)
References
Heineman et al., 1995: Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of virology. 1995; 69(12); 8109-8113. [PubMed: 7494331].
rORFV-CSFV-E2
Vaccine Information
  • Vaccine Ontology ID: VO_0004768
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • E2 gene engineering:
    • Type: Recombinant vector construction
    • Description: Using the new recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E. (Voigt et al., 2007).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Voigt et al., 2007) the recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E2 glycoprotein to protect CSFV chellange.
  • Immunization Route: Intramuscular injection (i.m.)
References
Voigt et al., 2007: Voigt H, Merant C, Wienhold D, Braun A, Hutet E, Le Potier MF, Saalmüller A, Pfaff E, Büttner M. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine. 2007; 25(31); 5915-5926. [PubMed: 17600594].
rORFV-D1701-V-HAh5n (H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004765
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: ORFV recombinants expressing the hemagglutinin (HA) or nucleoprotein (NP) of the highly pathogenic avian influenza virus (HPAIV) H5N1 (Rohde et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Rohde et al., 2013: Rohde J, Amann R, Rziha HJ. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus. PloS one. 2013; 8(12); e83802. [PubMed: 24376753].
rORFV-p40(Borna disease virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004769
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: The highly attenuated Orf virus strain D1701 was used to generate a recombinant virus (D1701-VrVp40) expressing nucleoprotein p40 of Borna disease virus (Henkel et al., 2005).
  • Immunization Route: Intramuscular injection (i.m.)
References
Henkel et al., 2005: Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology. 2005; 79(1); 314-325. [PubMed: 15596826].
rORFV-PRV-gC/gD
Vaccine Information
  • Vaccine Ontology ID: VO_0004770
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Based on the attenuated ORFV strain D1701-V, recombinants were produced that express the glycoproteins gC (D1701-VrVgC) or gD (D1701-VrVgD) of the alphaherpesvirus of swine, pseudorabies virus (PRV) (Fischer et al., 2003).
  • Immunization Route: Intramuscular injection (i.m.)
References
Fischer et al., 2003: Fischer T, Planz O, Stitz L, Rziha HJ. Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice. Journal of virology. 2003; 77(17); 9312-9323. [PubMed: 12915547].
rORFV-RabG
Vaccine Information
  • Vaccine Ontology ID: VO_0004766
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • RABVgp1 nucleoprotein N gene engineering:
    • Type: Recombinant vector construction
    • Description: Orf virus (ORFV) recombinant, D1701-V-RabG, expressing the rabies virus (RABV) glycoprotein that is correctly presented on the surface of infected cells without the need of replication or production of infectious recombinant virus(Amann et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Orf virus (ORFV) recombinant, D1701-V-RabG, expressing the rabies virus (RABV) glycoprotein (Amann et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Amann et al., 2013: Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O, Rziha HJ. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. Journal of virology. 2013; 87(3); 1618-1630. [PubMed: 23175365].
rORFV-RHDV-VP60
Vaccine Information
  • Vaccine Ontology ID: VO_0004767
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Rabbit
  • ORF1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of the calicivirus, rabbit hemorrhagic disease virus (RHDV) (Rohde et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Rohde et al., 2011) Anew recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of RHDV.
  • Immunization Route: Intramuscular injection (i.m.)
References
Rohde et al., 2011: Rohde J, Schirrmeier H, Granzow H, Rziha HJ. A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV). Vaccine. 2011; 29(49); 9256-9264. [PubMed: 22001119].
rPFV-CSFV-E0
Vaccine Information
  • Vaccine Ontology ID: VO_0004748
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: CSFV E0 gene was amplified from the plasmid pMD18-T-E0 by PCR and cloned into the FPV-P11 and FPV-pSY (Wang et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
References
Wang et al., 2008: Wang YH, Li PH, Zhang MT, Zhang YM. [Construction of recombinant fowlpox virus expressing E0 gene of classical swine fever virus shimen strain and the animal immunity experiment]. Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui]. 2008; 24(1); 59-63. [PubMed: 18320824].
rPIV5-H3 (influenza virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004783
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
    • Vactor Name:
    • VO ID: VO_0001112
    • Description: The bovine parainfluenza virus vaccine vector can be used to express other pathogen's gene (Tompkins et al., 2007).
  • Preparation: DNA vaccine expressing full-length consensus-sequence M2 (M2-DNA) induced M2-specific antibody responses (Tompkins et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].
rSPV-HA1 (Swine influenza virus H1N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004636
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant swinepox virus (rSPV-HA1) expressing hemagglutinin (HA1) of H1N1 SIV (Xu et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
References
Xu et al., 2012: Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C. Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs. Vaccine. 2012; 30(20); 3119-3125. [PubMed: 22391400].
rSPV/H3-2A-H1
Vaccine Information
  • Vaccine Ontology ID: VO_0004755
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: Recombinant swinepox virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2 (Xu et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Xu et al., 2013: Xu J, Yang D, Huang D, Xu J, Liu S, Lin H, Zhu H, Liu B, Lu C. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses. Archives of virology. 2013; 158(3); 629-637. [PubMed: 23135159].
RSV-H7
Vaccine Information
  • Vaccine Ontology ID: VO_0004724
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Plasmid DNAs used for vector construction included pSV153, containing the H7 gene of Seal/Mass/80 (H7N7) (17) (Hunt et al., 1988).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: The HA selected for expression was that of A/Seal/Mass/1/80 (H7N7) (Seal/Mass/80) (Hunt et al., 1988).
  • Immunization Route: Intramuscular injection (i.m.)
References
Hunt et al., 1988: Hunt LA, Brown DW, Robinson HL, Naeve CW, Webster RG. Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. Journal of virology. 1988; 62(8); 3014-3019. [PubMed: 2839718].
rVEE-Ebola-NP
Vaccine Information
  • Vaccine Ontology ID: VO_0004805
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Antigen: Ebola virus nucleoprotein (NP) (Wilson and Hart, 2001)
  • NP from Zaire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
Wilson and Hart, 2001: Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. Journal of virology. 2001; 75(6); 2660-2664. [PubMed: 11222689].
rVEE-HA(H1N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004784
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: The HA gene was transferred into the VEE vector (Davis et al., 1996).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: (Davis et al., 1996) a VEE vector containing the complete influenza virus hemagglutinin (HA) gene of H1N1 influenza virus.
  • Immunization Route: Intramuscular injection (i.m.)
References
Davis et al., 1996: Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. Journal of virology. 1996; 70(6); 3781-3787. [PubMed: 8648713].
rvOka-HN (mumps virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004709
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HN gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant varicella-zoster virus (VZV) Oka vaccine strain (vOka) that contained the mumps virus (MuV) hemagglutinin-neuraminidase (HN) gene, inserted into the site of the ORF 13 gene (Somboonthum et al., 2007).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant varicella-zoster virus (VZV) Oka vaccine strain (vOka) that contained the mumps virus (MuV) hemagglutinin-neuraminidase (HN) gene, inserted into the site of the ORF 13 gene by using the bacterial artificial chromosome (BAC) system in Escherichia coli (Somboonthum et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
rVSV- SEBOV-GP and -VP40
Vaccine Information
  • Vaccine Ontology ID: VO_0004661
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • NP from Zaire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
    • Detailed Gene Information: Click Here.
  • VP40 from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: rVSV-expressing SEBOV-GP and -VP40 (Marzi et al., 2011; Falzarano et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Falzarano et al., 2011: Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. The Journal of infectious diseases. 2011; 204 Suppl 3; S1082-1089. [PubMed: 21987745].
Marzi et al., 2011: Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. The Journal of infectious diseases. 2011; 204 Suppl 3; S1066-1074. [PubMed: 21987743].
rVSV-EBOV
Vaccine Information
  • Vaccine Ontology ID: VO_0004660
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Zaire ebolavirus (ZEBOV) (Falzarano et al., 2011).
    • Detailed Gene Information: Click Here.
  • GP from Cote d'Ivoire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Côte d’Ivoire ebolavirus (CIEBOV) (Falzarano et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein (Falzarano et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
References
Falzarano et al., 2011: Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. The Journal of infectious diseases. 2011; 204 Suppl 3; S1082-1089. [PubMed: 21987745].
rVSVΔG-ANDV-GPC
Vaccine Information
  • Vaccine Ontology ID: VO_0004662
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
SabRV-SIV
Vaccine Information
  • Vaccine Ontology ID: VO_0004704
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env gene engineering:
    • Type: Recombinant vector construction
    • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
    • Detailed Gene Information: Click Here.
  • env receptor binding subunit gene engineering:
    • Type: Recombinant vector construction
    • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
    • Detailed Gene Information: Click Here.
  • gag-pol gene engineering:
    • Type: Recombinant vector construction
    • Description: To construct pSabRV1, first the EcoRI and XhoI sites upstream of the T7 promoter of pS1 were eliminated to create plasmid pS1XT. Then the 747-bp BstEII fragment of pMoV2.11—containing the duplicated 2Apro cleavage site, the 5-glycine spacer, and the EcoRI, NotI, and XhoI cloning sites—was swapped into pS1XT to create pSabRV1 (Crotty et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: New poliovirus vectors based on Sabin 1 and 2 vaccine strain viruses were constructed, and these vectors were used to generate a series of new viruses containing SIV gag, pol, env, nef, and tat in overlapping fragments (Crotty et al., 2001).
  • Immunization Route: Intramuscular injection (i.m.)
References
Crotty et al., 2001: Crotty S, Miller CJ, Lohman BL, Neagu MR, Compton L, Lu D, Lü FX, Fritts L, Lifson JD, Andino R. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. Journal of virology. 2001; 75(16); 7435-7452. [PubMed: 11462016].
Schmidt-Ruppin Rous sarcoma virus-H7 (H7N7)
Vaccine Information
  • Vaccine Ontology ID: VO_0004677
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Description: An influenza virus hemagglutinin gene, H7, has been expressed in a replication-competent Schmidt-Ruppin Rous sarcoma virus-derived vector (Hunt et al., 1988).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, (Hunt et al., 1988).
  • Immunization Route: Intramuscular injection (i.m.)
References
Hunt et al., 1988: Hunt LA, Brown DW, Robinson HL, Naeve CW, Webster RG. Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. Journal of virology. 1988; 62(8); 3014-3019. [PubMed: 2839718].
SG33-VP2/5
Vaccine Information
  • Vaccine Ontology ID: VO_0004706
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Sheep
  • Vector:
  • Preparation: MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012)
  • Immunization Route: Other
References
Top et al., 2012: Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine. 2012; 30(9); 1609-1616. [PubMed: 22244980].
SIV recombinant vector vaccine rAd5/rLCMV
Vaccine Information
  • Vaccine Ontology ID: VO_0004564
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Macaques
  • Antigen: a mismatched SIV envelope (Env) gene derived from simian immunodeficiency virus SIVmac239 (Flatz et al., 2012)
  • Vector:
  • Immunization Route: Intramuscular injection (i.m.)
References
Flatz et al., 2012: Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. Journal of virology. 2012; 86(15); 7760-7770. [PubMed: 22593152].
Toxminus-PLD toxoid
Vaccine Information
  • Vaccine Ontology ID: VO_0004795
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: (Hodgson et al., 1994) An inactive form of the Corynebacterium pseudotuberculosis phospholipase D (PLD) gene was constructed and expressed in a PLD-negative strain (designated Toxminus) of C. pseudotuberculosis.
  • Immunization Route: Intramuscular injection (i.m.)
References
Hodgson et al., 1994: Hodgson AL, Tachedjian M, Corner LA, Radford AJ. Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis. Infection and immunity. 1994; 62(12); 5275-5280. [PubMed: 7960105].
Trovac-AI-H5
Vaccine Information
  • Tradename: Trovac AI H5
  • Manufacturer: Merial
  • Vaccine Ontology ID: VO_0000839
  • Type: Recombinant vector vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Pig
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Different vaccines expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) (Kyriakis et al., 2009).
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Fowlpox virus-vectored H5 (Bublot et al., 2006)
References
Bublot et al., 2006: Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR. Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences. 2006; 1081; 193-201. [PubMed: 17135511].
Kyriakis et al., 2009: Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine. 2009; 27(16); 2258-2264. [PubMed: 19428840].
vFP89-H5
Vaccine Information
  • Vaccine Ontology ID: VO_0004620
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant vaccine (vNDV-H5) encoding an optimized synthetic haemagglutinin gene from a clade 2.2.1 H5N1 highly pathogenic (HP) avian influenza virus (AIV), either as a single administration or as a boost following a prime inoculation with a fowlpox vectored vaccine (vFP89) encoding a different H5 HP haemagglutinin from an Irish H5N8 strain (Niqueux et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Niqueux et al., 2013: Niqueux E, Guionie O, Amelot M, Jestin V. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus. Vaccine. 2013; 31(38); 4121-4128. [PubMed: 23845804].
vFP89-HA (H5N1 HPAI virus)
Vaccine Information
  • Vaccine Ontology ID: VO_0004745
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant protein preparation
    • Description: Fowlpox (FP) vector vaccines expressing the native hemagglutinin (HA) gene from H5N8 (Bublot et al., 2010).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Compare one (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 and the other (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003 (Bublot et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Bublot et al., 2010: Bublot M, Manvell RJ, Shell W, Brown IH. High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens. Avian diseases. 2010; 54(1 Suppl); 257-261. [PubMed: 20521642].
VSV*ΔG-H5 (H5N1)
Vaccine Information
  • Vaccine Ontology ID: VO_0004659
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • HA gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: A recombinant vesicular stomatitis virus (VSV) vector was used to express HA of subtype H5 (Halbherr et al., 2013).
  • Immunization Route: Intramuscular injection (i.m.)
References
Halbherr et al., 2013: Halbherr SJ, Brostoff T, Tippenhauer M, Locher S, Berger Rentsch M, Zimmer G. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus. PloS one. 2013; 8(6); e66059. [PubMed: 23762463].
YF17D- HIV-1 p24
Vaccine Information
  • Vaccine Ontology ID: VO_0004690
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Vector:
  • Preparation: HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24) (Franco et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
References
Franco et al., 2010: Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine. 2010; 28(35); 5676-5685. [PubMed: 20600494].